QRA special issue
This article was originally published in The Rose Sheet
Executive Summary
Regulatory Toxicology and Pharmacology journal publishes a special issue on Research Institute for Fragrance Material's Dermal Sensitization Quantitative Risk Assessment (QRA) methodology, according to Nov. 18 release from RIFM. This is the most current and comprehensive publication of the methodology available, RIFM notes. "This new methodology is a major improvement over the former approach because it specifically addresses the elements of exposure-based risk assessment that are unique to the induction of dermal sensitization, while being consistent with the principles of general toxicology risk assessment," says Dr. Anne Marie Api, RIFM VP-human health sciences. Under QRA system, consumer products are grouped into 11 categories based on the level of exposure a consumer can expect from using the product; safe concentration limit is then set for a given fragrance ingredient in each category. RIFM is in talks with European Commission's Scientific Committee on Consumer Products, which has hesitated to embrace QRA (1"The Rose Sheet" Oct. 27, 2008, p. 5). The six articles in the special QRA issue are available through the RIFM Web site
You may also be interested in...
RIFM, European Scientists Work To Iron Out Differences On QRA Methodology
The Research Institute for Fragrance Materials is in talks with industry representatives and European scientific authorities regarding its quantitative risk assessment (QRA) approach to fragrance sensitization, which has been received with varying degrees of enthusiasm
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.